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Abstract
Background Danon disease is a neuromuscular disorder
with variable expression in the eye. We describe a family
with Danon disease and cone-rod dystrophy (CRD).
Methods Affected males of one family with Danon were
invited for an extensive ophthalmologic examination,
including color vision testing, fundus photography, Gold-
mann perimetry, full-field electroretinogram (ERG), and
SD-OCT. Previous ophthalmologic data were retrieved
from medical charts. The LAMP2 and RPGR gene were
analyzed by direct sequencing.
Results Two siblings had no ocular phenotype. The third
sibling and a cousin developed CRD leading to legal
blindness. Visual acuity deteriorated progressively over
time, color vision was severely disturbed, and ERG showed
reduced photopic and scotopic responses. SD-OCT revealed
thinning of the photoreceptor and RPE layer. Visual fields
demonstrated central scotoma. The causal mutation was p.
Gly384Arg in LAMP2; no mutations were found in RPGR.
Conclusions This is the first description of CRD in Danon
disease. The retinal phenotype was a late onset but severe
dystrophy characterized by loss of photoreceptors and RPE
cells. With this report, we highlight the importance of a
comprehensive ophthalmologic examination in the clinical
work-up of Danon disease.
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Introduction
Danon disease is a rare genetic condition caused by
mutations in the X-linked (XL) lysosome-associated
membrane protein gene (LAMP2). Danon consists of
triad muscle weakness, cardiomyopathy, and mental
impairment. The mortality rate in males is high; the
most frequent cause of death is a heart arrhythmia.
Female carriers can show a mild phenotype, often
restricted to cardiomyopathy [1, 2].
To date, ophthalmologic involvement has been described
in only a few cases. Retinal abnormalities were reported;
however, detailed work-up including psychophysical test-
ing was lacking [1, 3–5]. It was therefore unclear which
retinal cell types were affected, whether it included rods
and cones, and whether the disease progressed to legal
blindness. Here, we present the results of a comprehensive
ophthalmologic examination in a small Danon family with
cone-rod dystrophy (CRD) due to an uncommon missense
mutation in LAMP2.
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Methods
Clinical examination
A proband with Danon disease presented at our clinic with
visual complaints. After his visit, we invited his three cousins
with Danon for an eye examination. They all underwent an
extensive examination, including best-corrected Snellen visu-
al acuity (BCVA), refractive error, color vision testing
(American Optical Hardy–Rand–Rittler test), full-field elec-
troretinogram (ERG), fundus photography centered on the
macula (TRC 50IX; Topcon, Tokyo, Japan), and spectral-
domain optical coherence tomography (SD-OCT). ERGs
incorporated the recommendations of the ISCEV [6]. Direct
sequencing of the entire coding regions and flanking
sequences of the genes LAMP2 and RPGR was performed
at the Netherlands Institute of Neurosciences. The additional
RPGR screening was performed to exclude other genetic
causes. To the best of our knowledge, this gene is the only
known causal gene for XL-CRD to date [7]. The study was
approved by the Medical Ethics Committee of Erasmus
Medical Center, and adhered to the tenets of the Declaration
of Helsinki. The participants provided signed, informed
consent for participation in the study, retrieval of medical
records, and use of blood and DNA for research.
Results
The proband (III-1) and three of the four cousins (III-2, III-4,
III-5) had Danon disease caused by a missense mutation,
c.1150 G>C, leading to an amino acid change (p.Gly384Arg)
in splice variant B (exon 9B) of the LAMP2 gene (reference
sequence NM_013995.1; nomenclature according to http://
www.hgvs.org/Mutnomen/). One cousin was unaffected (III-
3), and had no LAMP2 mutation. No RPGR mutations were
found in the cousins with CRD (Fig. 1a). Table 1 shows the
clinical findings of this family.
Case 1
Proband III-1 developed visual problems long before other
symptoms were apparent. Visual decline and photophobia
started at age 49 years. At age 69, BCVA deteriorated to hand
movements at 1 meter. Fundus examination revealed a bull’s
eye maculopathy with a normal peripheral retina, SD-OCT
showed thinning of the outer segments and RPE in the macula
(Fig. 1b). On ERG, cone and rod responses were both
severely reduced; the latter were asymmetrically affected with
more reduced rod amplitudes in the left eye and nearly normal
amplitudes in the right eye. However, latency times were
increased in both eyes (Fig. 1f). Muscle weakness started at
age 64, and progressed rapidly to wheelchair dependency [8].
Case 2
Cousin III-2 was 68 years old at time of last examination, and
had no visual complaints. BCVAwas 1.0 and ophthalmoscopy
showed no retinal abnormalities (Fig. 1d). Other physical
signs of Danon were weakness of the shoulder, upper arm,
and distal legs.
Case 3
Cousin III-4 was 66 years old at time of last
examination, and had no ocular abnormalities (Fig. 1e).
Fig. 1 The pedigree, fundus photographs, spectral-domain optical
coherence tomography (SD-OCT), electroretinogram (ERG) and a
schematic representation of the localization of the LAMP2 protein in
the retinal pigment epithelium (RPE) of the X-linked family with Danon
disease and cone-rod dystrophy (CRD). a The pedigree shows two
affected siblings with CRD and the mutation p.Gly384Arg in the
LAMP2 gene; no mutations in the RPGR gene. Open square:
unaffected male; black square: affected males with Danon disease and
CRD; half-open square: affected males with Danon disease but without
CRD; dashed symbols denote deceased individuals. b Fundus photo-
graph of the left eye of the proband III-1, performed at age 69, showing
RPE clumping and atrophy in the macula. The arrow denotes the
position of the SD-OCT image, showing thinning of the outer segments
and RPE, pigment clumping at the RPE layer and in the photoreceptor
cell layer, and window defects due to atrophy of the RPE. c Fundus
photograph of the right eye of the affected cousin III-5, performed at age
64, showing RPE atrophy in the macula. The arrow denotes the position
of the SD-OCT image, showing a thinner but intact photoreceptor layer
and thinning of the RPE cell layer. The SD-OCT cross section is not
fully perpendicular. d Fundus photograph of the left eye of the
unaffected cousin III-2, performed at age 68, showing a normal macular
appearance. e Fundus photograph of the left eye of the unaffected
cousin III-4, performed at age 66, showing a normal macular
appearance. f Electroretinogram of proband III-1 (69 years) performed
with the standard International Society for Clinical Electrophysiology of
Vision (ISCEV) protocol. Replications of the responses are shown as
thin traces, the average as solid. ERGs of 17 age-related normal subjects
(63 ± 5 years) were analyzed in terms of amplitudes and peak latencies
of the relevant components, of which the two SD criteria are mentioned
below. In the dark-adapted state, the b-onset amplitudes were reduced to
80 μVand 39 μV for right and left eye respectively (normal: ≥105 μV),
and the b-latencies were increased to 125 ms and 128 ms for right and
left eye respectively (normal: ≤115 ms) (0.001 cd.s/m2). The b-a
amplitudes for the 3 cd.s/m2 were 190 μVand 162 μV for the right and
left eye respectively (normal: ≥172 μV). The a-latencies were 25 ms and
29 ms (normal ≤19 ms), and the b-latencies were 72 ms and 67 ms for
the right and left eye respectively (normal: ≤62 ms). Note the reduced
rod-specific response is more severely reduced in the left eye. In the
light-adapted state, the b-a amplitudes were reduced to 64 μV and
43 μV for right and left eye respectively (normal ≥68 μV), and the b-
latencies were increased to 41 ms and 40 ms for right and left eye
respectively (normal: ≤34 ms). The diminished cone-specific function
was also proven by the mildly reduced amplitudes of the cone-specific
response to 30 Hz flicker stimulation (45 μV and 35 μV, for right and
left eye respectively (normal ≥37 μV), and increased peak latencies to
37 ms and 38 ms for right and left eye respectively (normal: ≤33 ms). g
Schematic drawing showing the presumed localization of the LAMP2
protein in the RPE lysosome, and the accumulation of outer segment
remnants in the RPE cell in Danon disease. Abbreviation: OS: outer
segments of photoreceptor cells
b
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He had suffered from a generalized proximal muscle
weakness in arms and legs since the age of 45, which led
to wheelchair dependency. His two daughters appeared to
be non-affected.
Case 4
Cousin III-5 had had a gradually deteriorating visual
acuity since his thirties to 0.05 at age 64 years. Fundus
examination revealed a bull’s eye maculopathy and a
peripheral salt-and-pepper retinopathy The SD-OCT
showed a thinner but intact photoreceptor layer and thinning
of the RPE layer (Fig. 1c). Predominantly cone responses
were more severely reduced than rod responses on ERG.
Goldmann perimetry revealed a central scotoma and a
reduced sensitivity in the periphery. The patient suffered
from muscle weakness since childhood, and became
wheelchair-dependent at age 40. He developed a hypertro-
phic cardiomyopathy. The daughter of this patient suddenly
died at the age of 29 due to cardiomyopathy.
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Discussion
In our family with Danon disease, two of the four
affected males presented with all features of CRD: a
progressively deteriorating visual acuity, severe color
vision disturbances, a central visual field defect on
perimetry, and reduced photopic and scotopic responses
on ERG. The onset in this family was relatively late, i.e.,
middle-age, and visual acuity declined to legal blindness
within 2 decades thereafter.
In the retina, strong expression of LAMP2 has been
demonstrated in the lysosomes of RPE cells [5]. These
lysosomes play a crucial role in the constant renewal of
cone and rod outer segments. Daily, at least 2,000–4,000
packets of shedded discs are phagocytosed by the RPE, and
subsequently imported and degraded into the lysosome.
Mutations in the LAMP2 gene lead to RPE lysosome
dysfunction, leading to accumulation of deposits and
ultimately cell death. Eventually, this will lead to loss of
cone and rod photoreceptor cells (Fig. 1g).
Previously described cases with ophthalmologic in-
volvement in Danon disease had frameshift or nonsense
mutations in the LAMP2 gene, leading to absence of
the protein. The family of this report carried a recently
identified missense mutation (p.Gly384Arg) in exon 9
of the LAMP2 gene, allowing formation of the protein
[8]. An important function of exon 9 is the creation of two
different splice products, LAMP2a and LAMP2b, both
shown to be expressed in RPE cells [5]. Gly384Arg is
located in the coding sequence for splice variant LAMP2b,
jeopardizing function of only this specific isoform. The
late onset of the two affected cousins in our family could
be explained by the presence of this residual LAMP2
protein.
It remains intriguing why not all family members
with a pathogenic mutation in the LAMP2 gene
developed CRD. The non-expression in the two carriers
of the p.Gly384Arg mutation (III-2, III-4) suggests that
a normal function of lysosomes in the RPE can be
maintained, despite a mutation in LAMP2. Other
lysosomal proteins such as LAMP1 are also capable of
phagocytosis of autophagic material in the RPE, and
may compensate for a defective LAMP2 protein [9].
The presence of protective environmental factors in the
non-affected siblings which prohibit lysosomal degrada-
tion, or a still unidentified mutation in another gene that
explains CRD, are possible explanations.
In summary, this is the first description of a family with
CRD and a rare missense mutation in the LAMP2 gene.
CRD belongs to the clinical spectrum of Danon disease,
and we therefore recommend incorporation of a compre-
hensive ophthalmologic examination into the regular
clinical work-up of Danon patients.Ta
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